RecruitingWarts
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Sponsor: Western Institute for Veterans Research
You may qualify if…
- ✓ 1. Must be able to understand and provide written informed consent
- ✓ 2. Age 18 or older
- ✓ 3. Clinical diagnosis of cutaneous warts
- ✓ 4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)
You may not qualify if…
- ✕ 1. Untreated cutaneous warts
- ✕ 2. Anogenital warts
- ✕ 3. Oral warts
- ✕ 4. Treatment for cutaneous warts in the past 4 weeks
- ✕ 5. Active acute illness
- ✕ 6. Immunosuppression
- ✕ 7. Known hypersensitivity to HPV vaccination
- ✕ 8. Subjects may not receive any other investigational treatment
Where it's recruiting
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT05625633 · last updated 2024-04-05